Opus Genetics, Inc.
IRDNasdaqHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $14.2M | $11.0M | $19.0M | $39.9M | $589,000 | $0 |
| Operating income | −$38.6M | −$62.1M | −$10.6M | $18.2M | −$22.7M | −$20.0M |
| Net income | −$49.6M | −$57.5M | −$10.0M | $17.9M | −$56.7M | −$24.6M |
| Total assets | $50.2M | $36.9M | $53.9M | $49.0M | $26.1M | $17.7M |
| Total liabilities | $34.9M | $11.3M | $4.0M | $2.8M | $3.9M | $31.1M |
| Equity | $15.3M | $6.7M | $49.9M | $46.2M | $22.2M | −$13.5M |
| EPS (diluted) | $-0.80 | $-2.15 | $-0.46 | $0.87 | $-3.82 | $-5.28 |
| Shares out. | 45.5M | 24.8M | 20.9M | 19.0M | 10.9M | 4.0M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −271.9%
- Net margin
- −349.3%
- Return on equity
- −323.1%
- Return on assets
- −98.7%
- Return on capital (ROCE)
- −90.9%
- Liabilities / assets
- 69.5%
- Debt / equity
- 2.27×
- Book value / share
- $0.34
- Revenue growth (YoY)
- 29.1%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -11.42distress
- Accruals / assets
- −28.5%clean
- Piotroski F-Score
- 4/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 severe● 3 warning● 2 good- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- Revenue is growing year-over-year
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗May 18, 2010
- NT 10-Qmissed a reporting deadline ↗Nov 9, 2009
- NT 10-Qmissed a reporting deadline ↗Aug 16, 2005
- NT 10-Qmissed a reporting deadline ↗May 17, 2005
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 1/2Recruitingreadout ~2028-06-15Safety and Tolerability Subretinal OPGx-001 for LCA5-Associated Inherited Retinal Degeneration (LCA5-IRD) and Non-interventional Arm With Untreated Patients
- Phase 1/2Recruitingreadout ~2030-08Safety and Tolerability of Subretinally Injected OPGx-BEST1 in Patients With Best Vitelliform Macular Dystrophy (BVMD) or Autosomal-Recessive Bestrophinopathy (ARB)
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Foundation Fighting Blindness Retinal Degeneration FundActivist (13D)May 20, 2026
- Caligan Partners LpPassive (13G)May 15, 2026
- Perceptive Advisors LlcPassive (13G)May 15, 2026
- Balyasny Asset Management L.P.Passive (13G)May 15, 2026
- Nantahala Capital Management, LlcPassive (13G)May 15, 2026
- Bios Fund Iii, LpPassive (13G)May 13, 2026
- Adage Capital Management, L.P.Passive (13G)May 13, 2026
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 3.1M | 3.2 | +55.5% |
| Apr 30, 2026 | 2.0M | 2.2 | +10.7% |
| Apr 15, 2026 | 1.8M | 2.8 | -2.1% |
| Mar 31, 2026 | 1.8M | 2.8 | -8.3% |
| Mar 13, 2026 | 2.0M | 1.5 | +81.3% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operationsMay 12, 2026
- New financial obligationApr 24, 2026
- Shareholder voteApr 22, 2026
- Director / officer changeApr 7, 2026
- Entered a material agreement · Unregistered equity sale · Regulation FD disclosureApr 7, 2026
- Results of operationsMar 10, 2026
- Entered a material agreement · Results of operations · Unregistered equity sale · Amended charter or bylaws · Other material eventFeb 19, 2026
- Regulation FD disclosureJan 12, 2026
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SCHEDULE 13D/AMay 20, 2026
- 4PRIMARY DOCUMENTMay 20, 2026
- SCHEDULE 13G/AMay 15, 2026
- SCHEDULE 13G/AMay 15, 2026
- SCHEDULE 13GMay 15, 2026
- SCHEDULE 13G/AMay 15, 2026
- S-8May 14, 2026
- SCHEDULE 13G/AMay 13, 2026
- SCHEDULE 13GMay 13, 2026
- 10-QMay 12, 2026
- 8-KMay 12, 2026
- 4FORM 4Apr 27, 2026
- 4FORM 4Apr 27, 2026
- 4FORM 4Apr 27, 2026
- 4FORM 4Apr 27, 2026
Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.